CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Novo Nordisk A/S's Wegovy, a semiglutide injectable medicine, is now the primary weight loss drug offered on CVS's standard formulary, a list of medications an insurance plan covers. The news was not ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Eli Lilly on Thursday downplayed CVS Health’s decision to drop the company’s obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still ...

CVS Health Corp.CVS-0.78%decrease; red down pointing triangle tapped a former Eli Lilly & Co. finance chief to run its pharmacy benefit business as the drugstore giant works to complete an ...

Eli Lilly will deliver the $812.5 million in doses through Jan. 31, 2021, with at least 350,000 to be delivered by the end of December, the drugmaker announced Wednesday.

CVS Health Corp. will administer Eli Lilly and Co.’s COVID-19 treatment in patients’ homes and in long-term care facilities through a program with the U.S. government’s Operation Warp Speed ...

CVS Health Corp. will administer Eli Lilly and Co.’s COVID-19 treatment in patients’ homes and in long-term care facilities through a program with the U.S. government’s Operation Warp Speed ...

Eli Lilly (LLY) shares slid at the open despite topping first quarter estimates, with investors reacting to the company lowering its full-year profit outlook. Investors are also reacting to a new ...